Skip to main content

Advertisement

SpringerLink
Log in

Serum level of YWHAG as a diagnostic marker of cognitive impairment in Parkinson’s disease patients

  • Original article
  • Published:
Acta Neurologica Belgica Aims and scope Submit manuscript

Abstract

Background

Identifying reliable biomarkers for early detection and prediction of cognitive impairment in Parkinson’s disease (PD) is crucial for optimal patient care. This study set out to investigate the potential of YWHAG as a diagnostic biomarker for cognitive impairment in PD.

Methods

We enrolled a total of 331 PD patients and selected 241 patients that met the criteria for cognitive impairment analysis. The patients were classified into three groups: PD-NC: PD patients with normal cognition, PD-MCI: PD patients with mild cognitive impairment, and PD-D: PD patients with dementia. ELISA was employed to assess YWHAG expression, as well as the neurofilament light chain (NfL). Additionally, cognitive impairment was evaluated using MoCA scores. Correlation analysis and receiver operating curve analysis (ROC) were performed to clarify the relationship between YWHAG expression and cognitive impairment.

Results

Our findings revealed a significant upregulation of YWHAG expression in both the PD-MCI and PD-D groups compared to the PD-NC group. This observation aligned with the elevated expression of NfL in the PD-MCI and PD-D groups. YWHAG and NfL expression levels displayed negative correlations with MoCA scores and positive associations with age. Furthermore, ROC curve analysis demonstrated the diagnostic efficacy of YWHAG expression in distinguishing individuals with PD-NC, PD-MCI, and PD-D.

Conclusions

Our findings indicate that YWHAG could serve as a promising biomarker for cognitive impairment in PD. The upregulation of YWHAG expression in PD-MCI and PD-D groups, its association with cognitive impairment, and its correlations with MoCA scores and NfL levels support its potential clinical utility.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Aarsland D, Batzu L, Halliday GM, Geurtsen GJ, Ballard C, Ray Chaudhuri K, Weintraub D (2021) Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers 7:47

    Article  PubMed  Google Scholar 

  2. Brandão PRP, Munhoz RP, Grippe TC, Cardoso FEC, e Castro BM, Titze-de-Almeida R, Tomaz C, Tavares MCH (2020) Cognitive impairment in Parkinson’s disease: a clinical and pathophysiological overview. J Neurol Sci 419:117177

    Article  PubMed  Google Scholar 

  3. Weintraub D, Comella CL, Horn S (2008) Parkinson’s disease–Part 1: pathophysiology, symptoms, burden, diagnosis, and assessment. Am J Manag Care 14:S40–S48

    PubMed  Google Scholar 

  4. Svenningsson P, Westman E, Ballard C, Aarsland D (2012) Cognitive impairment in patients with Parkinson’s disease: diagnosis, biomarkers, and treatment. Lancet Neurol 11:697–707

    Article  PubMed  Google Scholar 

  5. Fan T-S, Liu SC-H, Wu R-M (2021) Alpha-synuclein and cognitive decline in Parkinson disease. Life 11:1239

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Mathew B, Parambi DG, Mathew GE, Uddin MS, Inasu ST, Kim H, Marathakam A, Unnikrishnan MK, Carradori S (2019) Emerging therapeutic potentials of dual-acting MAO and AChE inhibitors in Alzheimer’s and Parkinson’s diseases. Arch Pharm 352:1900177

    Article  CAS  Google Scholar 

  7. Han L, Tang J, Zhu S, Zhu J (2023) LncRNA SNHG7 knockdown aggravates hepatic ischemia-reperfusion injury and promotes apoptosis in hemorrhagic shock pregnant rats by modulating miR-34a-5p/YWHAG Axis. Mol Biotechnol 65:983–996

    Article  PubMed  CAS  Google Scholar 

  8. Zhu L, Chen L, Xu P, Lu D, Dai S, Zhong L, Han Y, Zhang M, Xiao B, Chang L (2020) Genetic and molecular basis of epilepsy-related cognitive dysfunction. Epilepsy Behav 104:106848

    Article  PubMed  Google Scholar 

  9. Ye X-G, Liu Z-G, Wang J, Dai J-M, Qiao P-X, Gao P-M, Liao W-P (2021) YWHAG mutations cause childhood myoclonic epilepsy and febrile seizures: molecular sub-regional effect and mechanism. Front Genet 12:632466

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Yanmei G, Daijun W, Xiaomei L, Yingying W, Meixia D, Li Y (2022) YWHAG promotes gastric cancer proliferation and migration via PI3K/AKT pathway. https://doi.org/10.21203/rs.3.rs-1402042/v1

  11. Aamodt WW, Waligorska T, Shen J, Tropea TF, Siderowf A, Weintraub D, Grossman M, Irwin D, Wolk DA, Xie SX (2021) Neurofilament light chain as a biomarker for cognitive decline in Parkinson disease. Mov Disord 36:2945–2950

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Lin C-H, Li C-H, Yang K-C, Lin F-J, Wu C-C, Chieh J-J, Chiu M-J (2019) Blood NfL: a biomarker for disease severity and progression in Parkinson disease. Neurology 93:e1104–e1111

    Article  PubMed  CAS  Google Scholar 

  13. Ramocki MB, Bartnik M, Szafranski P, Kołodziejska KE, Xia Z, Bravo J, Miller GS, Rodriguez DL, Williams CA, Bader PI (2010) Recurrent distal 7q11. 23 deletion including HIP1 and YWHAG identified in patients with intellectual disabilities, epilepsy, and neurobehavioral problems. Am J Hum Genet 87:857–865

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Weiner S, Junkkari A, Sauer M, Luikku A, Rauramaa T, Kokkola T, Herukka S-K, Blennow K, Zetterberg H, Leinonen V (2023) Novel cerebrospinal fluid biomarkers correlating with shunt responsiveness in patients with idiopathic normal pressure hydrocephalus. Fluids Barriers CNS 20:1–16

    Article  Google Scholar 

  15. Sathe G, Na CH, Renuse S, Madugundu AK, Albert M, Moghekar A, Pandey A (2019) Quantitative proteomic profiling of cerebrospinal fluid to identify candidate biomarkers for Alzheimer’s disease. Proteomics Clin Appl. https://doi.org/10.1002/prca.201800105

    Article  PubMed  Google Scholar 

  16. Dong L, Chang Q, Ma J, Liu C, Guo D, Li X, Yang D, Fan Y, Liang K, Li D (2023) Associations of blood UCH-L1 and NfL levels with cognitive dysfunction in Parkinson’s disease patients. Neurosci Lett 804:137219

    Article  PubMed  CAS  Google Scholar 

  17. Politis M (2014) Neuroimaging in Parkinson disease: from research setting to clinical practice. Nat Rev Neurol 10:708–722

    Article  PubMed  Google Scholar 

  18. Liu P, Kong L, Liang K, Wu Y, Jin H, Song B, Tan X (2020) Identification of dissociation factors in pancreatic Cancer using a mass spectrometry-based proteomic approach. BMC Cancer 20:1–9

    Google Scholar 

  19. Ng ASL, Tan YJ, Yong ACW, Saffari SE, Lu Z, Ng EY, Ng SYE, Chia NSY, Choi X, Heng D (2020) Utility of plasma neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson’s disease. Mol Neurodegener 15:1–8

    Article  Google Scholar 

  20. Buhmann C, Lezius S, Pötter-Nerger M, Gerloff C, Kuhle J, Choe Cu (2022) Age-adjusted serum neurofilament predicts cognitive decline in Parkinson’s disease (MARK-PD). Mov Disord 37:435–436

    Article  PubMed  Google Scholar 

  21. Zhou X, Wang Z, Xu B, Ji N, Meng P, Gu L, Li Y (2021) Long non-coding RNA NORAD protects against cerebral ischemia/reperfusion injury induced brain damage, cell apoptosis, oxidative stress and inflammation by regulating miR-30a-5p/YWHAG. Bioengineered 12:9174–9188

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  22. Kanani F, Titheradge H, Cooper N, Elmslie F, Lees MM, Juusola J, Pisani L, McKenna C, Mignot C, Valence S (2020) Expanding the genotype–phenotype correlation of de novo heterozygous missense variants in YWHAG as a cause of developmental and epileptic encephalopathy. Am J Med Genet A 182:713–720

    Article  PubMed  CAS  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Department of Neurology, Cangzhou Central Hospital, No.16 Xinhua West Road, Cangzhou, 061000, Hebei, China

    Yingying Peng, Lan Zhu, Limin Wang & Qian Li

  2. Department of Neurosurgery, Cangzhou Central Hospital, No.16 Xinhua West Road, Cangzhou, 061000, Hebei, China

    Qingling Bai

Authors
  1. Yingying Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lan Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qingling Bai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Limin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qian Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Qingling Bai.

Ethics declarations

Conflict of interest

The authors declared that they had no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Peng, Y., Zhu, L., Bai, Q. et al. Serum level of YWHAG as a diagnostic marker of cognitive impairment in Parkinson’s disease patients. Acta Neurol Belg (2024). https://doi.org/10.1007/s13760-023-02441-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s13760-023-02441-5

Keywords

Search

Navigation